Podcasts about anbo

Užsienio kultūrinės spaudos apžvalga.Kauno rotušėje atidaryta paroda „Miesto atmintis: archeologai“. Joje pristatomi du tos pačios archeologų kartos atstovai, pradėję darbuotis XX a. 9 dešimtmečio pradžioje: Dainius Balčiūnas ir Mindaugas Bertašius.Panevėžio Juozo Miltinio dramos teatre – paskutinė sezono premjera – Aleksandro Špilevojaus „Arrivederci“. Šiuo spektakliu A. Špilevojus atsisveikina ir su Juozo Miltinio dramos teatru bei palieka meno vadovo pareigas.Vytauto Bikulčiaus knygų apžvalga.Vytauto Didžiojo universitete buvo parengtos rekomendacijos dėstytojams, padedančios kurti įtraukesnę, aiškesnę ir supratingesnę mokymosi aplinką studentams, turintiems autizmo spektro sutrikimą.Lietuvos kompozitorių sąjunga paskelbė Lietuvos kompozitorių 2024 metų kūrinių penkioliktuką. Kviečiame susipažinti su kompozitoriaus Felikso Bajoro kūriniu „Arkos“ simfoniniam orkestrui.Rytoj Vilniuje prasideda XXVI Tarptautinis universitetų teatrų forumas. Šių metų forumo tema – ANBO kodas, skirta paminėti inžinieriaus Antano Gustaičio sukurto lėktuvo šimtmetį ir Lietuvos aviacijos kūrėjų metus.Sekmadienį, Motinos dienos proga, LRT Klasikoje bus pristatytas radijo spektaklis „Baltieji prieš juoduosius“, sukurtas pagal rašytojos Danutės Kalinauskaitės romaną.Ved. Justė Luščinskytė

Ką reiškia lydėti žmogų prieš jam mirštant? Ko tokioje situacijoje atsidūrusiam žmogui labiausiai reikia ir norisi? Pokalbis su Lina Jakele, viena pirmųjų Lietuvoje pradėjusių dirbti klinikinės sielovados srityje.Partizaniškos eilės virto daina „ Jūra kyla“. Klausysimės dainos ir pakalbėsime apie šių eilių ir jų autorės istoriją, šiandieninį partizanų kūrybos turinį ir skambesį. Laidoje dalyvauja Lietuvos gyventojų genocido ir resistencijos tyrimo centro istorikai Enrika Kripienė ir Andrius Tumavičius bei atilkėjai, dueto „Olita Duo“ nariai Gabija Kochanskaitė ir Robertas Žymantas.Eismo rubrikoje pokalbis su Lietuvos dviratininkų bendrijos pirmininku Pauliumi Bakučiu apie tai, ką reikia žinoti, norint dviračiu važinėti žiemą?2025-ieji – lėktuvo ANBO sukonstravimo 100-ečio ir Lietuvos aviacijos kūrėjų metai. Šia proga Ąžuolyno bibliotekoje Kaune pristatyta Rasos Gustaitis knyga „Skrydis“, kurioje ji rašo apie savo tėvą – Lietuvos aviacijos kūrėją, lėktuvų ANBO konstruktorių Antaną Gustaitį.Ką reiškia gyventi kaime, kurio apylinkėse, prieš pusantro šimto milijonų metų nukrito didžiulis meteoritas? Pokalbis iš Sukinių kaimo Ukmergės rajone.Ved. Agnė Skamarakaitė

Kultūrinės spaudos apžvalga.Kodėl Kinija bijo Mikės Pūkuotuko, o Rusija – ne?2025-ieji – lėktuvo ANBO sukonstravimo 100-mečio ir Lietuvos aviacijos kūrėjų metai. Minint šią progą Ąžuolyno bibliotekoje Kaune pristatyta Rasos Gustaitis knyga „Skrydis“.Klasikos koncertų salės rekomendacijos su Gabija Narušyte.Internete plinta dirbtinio intelekto sugeneruotos vaizdo klastotės. Nors kai kurios jų yra visai nekenksmingos, tačiau yra atveju, kai jos naudojamos rimtoms finansinėms aferoms ar kitiems nusikaltimams vykdyti. Kaip apsisaugoti?Vilniaus dailės akademijos Telšių galerijoje pristatyta tarpdisciplininio projekto paroda „Trys gyvenimo filosofijos“. Skulptūros ir juvelyrikos studentų darbai papildyti bibliniais įvaizdžiais ir motyvais.Aktorei Rasai Samuolytei – 50 metų. Pokalbis apie patį pirmąjį vaidmenį, atsiribojimą nuo personažo ir palinkėjimus sau.Kino kritikė Mantė Valiūnaitė apžvelgia filmą „Gera mergaitė“.Ved. Justė Luščinskytė

39-oji Ievos Simonaitytės premija bus įteikta rašytojams Mindaugui Miliniui ir Antanui Verkeliui už knygą „Mėmelio šturmo blefas“. Kas įkvėpė parašyti šią knygą?Šiaulių apskrities Povilo Višinskio viešojoje bibliotekoje atidaryta menotyrininkui profesoriui Vyteniui Rimkui dedikuota erdvė.Minint lėktuvo ANBO sukonstravimo 100-ečio ir Lietuvos aviacijos kūrėjų metus, pristatyta Rasos Gustaitis knyga „Skrydis“, kurioje ji pasakoja apie savo tėvą – Lietuvos aviacijos kūrėją, lėktuvų ANBO konstruktorių Antaną Gustaitį.Kokie Švietimo, mokslo ir sporto ministerijoje įvykusio susitikimo dėl Šiaulių „Juventos“ progimnazijos rezultatai?Rubrikos „Be kaukių“ svečias – aktorius ir bardas Saulius Bareikis.Ved. Marius Eidukonis

Šalia Šiaulių plytinčios Zoknių dvaro lygumos tarpukariu į dangų kėlė moderniausius 4-osios eskadrilės ANBO lėktuvus ir net glaudė Felikso Vaitkaus Lituanica II. Tačiau iki šių dienų išlikęs Antano Gustaičio vardo angaras mena ne tik Lietuvos aviacijos aukštumas, bet ir Šaltojo karo metus, kai Zoknių aerodromas atominio karo žemėlapyje buvo pažymėtas ryškiai raudona spalva. Dabar šiame, kažkada NATO įprasta kaimo vietove laikytame oro uoste, yra dislokuotos tos pačios organizacijos karinės oro pajėgos, saugančios visą Baltijos regioną. Šiais metais birželio pirmą dieną 93 gimtadienį atšventusio Zoknių aerodromo istorija nėra tik pasakojimas apie vieno mažo oro uosto raidą – tai puiki iliustracija, kokia turbulencija pastarąjį šimtmetį purtė visą Lietuvą. Įspėjimas! Šiauliečiai viso epizodo metu galimai nevaldomai aikčios nuo gerai pažįstamų pavadinimų ir vardų. Kaip lietuvis galėjo tapti pirmojo lėktuvo išradėju? Ką bendro turi vaikų darželio Kalėdos ir branduolinės bazės? Ir kas iš tikrųjų pavogė Viliaus plaukus? Atsakymai – jau dabar. Tinklalaidės epizodas parengtas bendradarbiaujant su Šiaulių apskrities Povilo Višinskio viešaja biblioteka vykdant projektą „20 metų Narystės, Apsaugos, Taikos ir Orumo (NATO)“. Projektą finansuoja Lietuvos kultūros taryba ir Šiaulių miesto savivaldybė.

Thanks to Anbo, Murilo, Clay, and Ezra for their suggestions this week! Let's learn about some bears! Further reading: Snack attack: Bears munch on ants and help plants grow Extinct vegetarian cave bear diet mystery unravelled Ancient brown bear genomes sheds light on Ice Age losses and survival The sloth bear has shaggy ears and floppy lips [photo from this site]: An absolute unit of a Kodiak bear in captivity [photo by S. Taheri - zoo, own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=1118252]: A polar bear: Show transcript: Welcome to Strange Animals Podcast. I'm your host, Kate Shaw. This week we're revisiting a popular topic, bears! We'll talk about some bears we've never covered before, with suggestions from Anbo, Clay, Ezra, and Murilo. We'll even discuss a small bear mystery which has mostly been solved by science. To start us off, Anbo wanted to learn about bears in general. We've had bear episodes before, but our last episode all about bears was way back in 2017, in episode 42. Some of our listeners weren't even born back then, which makes me feel super old. Bears live throughout much of the world today, but they evolved in North America around 38 million years ago. These ancestral bears were small, about the size of a raccoon, but they were successful. They spread into Asia via the land bridge Beringia, where they were even more successful than in North America, so successful that by around 30 million years ago, descendants of those earliest bear ancestors migrated from Asia back into North America. But it wasn't until the Pleistocene around 2 ½ million years ago that bears really came into their own. That's because bears are megafauna, and megafauna evolved mainly as an adaptation to increasingly cold climates. As the ice ages advanced, a lot of animals grew larger so they could stay warm more easily. Predators also had to grow larger as their prey became larger, since if you want to hunt an animal the size of a bison or woolly rhinoceros, you'd better be pretty big and strong yourself. Bears mostly weren't hunting animals that big, though. Modern studies suggest that overall, bears are omnivores, not fully carnivorous. Bears eat a lot of plant material even if you don't count the panda, which isn't very closely related to other bears. Even when a bear does eat other animals, they're not usually very big ones. Let's take Murilo's suggestion as an example, the sloth bear. The sloth bear lives in India and is increasingly vulnerable due to habitat loss and poaching. It's probably most closely related to the sun bear that we talked about in episode 234, which also lives in parts of South Asia. Both the sun bear and the sloth bear have long black hair and a white or yellowish V-shaped marking on the chest. The sloth bear's hair is especially long on its neck and shoulders, like a mane, and its ears even have long hair. The sloth bear stands around 3 feet high at the shoulder at most, or 91 cm, and a big male can be over 6 feet tall, or almost 2 meters, when he stands on his hind legs. This isn't gigantic for bears in general, but it's not small either. Scientists think the V-shaped marking on its chest warns tigers to leave the sloth bear alone, and tigers mostly do. If tigers think twice about attacking an animal, you know that animal has to be pretty tough. The sloth bear has massive claws on big paws. The claws can measure 4 inches long, or 10 cm, although they're not very sharp. The bear has an especially long muzzle but its teeth aren't very large. Like most bears, it's good at climbing trees and can run quite fast, and it swims well too. It even has webbed toes. With all this in mind, what do you think the sloth bear eats? I'll give you some more hints. It has loose, kind of flappy lips, especially the lower lip. It doesn't have any teeth in the front of its upper jaw. It mainly uses its huge claws to dig.

Thanks to Anbo and Siya for suggesting the mantis shrimp this week! The Kickstarter for some animal-themed enamel pins is still going on! Further reading: Rolling with the punches: How mantis shrimp defend against high-speed strikes The magnificent peacock mantis shrimp [picture by Cédric Péneau, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=117431670]: Show transcript: Welcome to Strange Animals Podcast. I'm your host, Kate Shaw. As invertebrate August continues, this week we have a topic suggested by Anbo and Siya. They both wanted to learn about the mantis shrimp! The mantis shrimp, which is properly called a stomatopod, is a crustacean that looks sort of like a lobster without the bulky front end, or a really big crayfish. Despite its name, it's not a shrimp although it is related to shrimps, but it's more closely related to lobsters and crabs. It can grow as much as 18 inches long, or 46 cm, but most are about half that size. Most are brown but there are hundreds of different species and some are various brighter colors like pink, blue, orange, red, or bright green, or a rainbow of colors and patterns. There are two things almost everyone knows about the mantis shrimp. One, it can punch so hard with its claws that it breaks aquarium glass, and two, it has 12 to 16 types of photoreceptor cells compared to 3 that humans have, and therefore it must be able to see colors humans can't possibly imagine. One of those things is right, but one is wrong, or at least partially wrong. We'll discuss both in a minute, but first let's learn the basics about these fascinating animals. The mantis shrimp lives in shallow water and spends most of its time in a burrow that it digs either in the sea floor or in crevices in rocks or coral, which it enlarges if necessary. Some species will dig elaborate tunnel systems while others just wedge themselves into any old crack that will hide them. It molts its exoskeleton periodically as it grows, like other crustaceans, and after that it either has to expand its burrow or move to a larger one. Most species live in tropical or subtropical areas, but some prefer more temperate waters. It has eight pairs of legs, which includes three pairs of walking legs, four pairs with claws that help it grasp items, and its front pair, which are hinged and look a little like the front legs of a praying mantis. That's where the “mantis” in mantis shrimp comes from, although of course it has lots of other names worldwide. In some places it's called the thumb splitter. The mantis shrimp has two eyes on stalks that move independently. Its brain extends into the eye stalks, and the section of the brain in the eye stalks, called the reniform body, is what processes vision. This allows it to process a lot of visual information very quickly. Reniform bodies have also been identified in the brains of some other crustaceans, including shrimp, crayfish, and some crabs. Scientists also think that the eyes themselves do a lot of visual processing before that information gets to the reniform body or the brain at all. In other words, part of the reason the mantis shrimp's eyes are so complicated and so unusual compared to other animals' eyes is because each eye is sort of a tiny additional brain that mainly processes color. The typical human eye can only sense three wavelengths of light, which correspond to red, green, and blue. The mantis shrimp has twelve different photoreceptors instead of three, meaning it can sense twelve wavelengths of light, and some species have even more photoreceptors. But while our brains are really good at synthesizing the three wavelengths of light we can see, combining them so that we see incredibly fine gradations of color in between red, green, and blue, the mantis shrimp doesn't process color the same way we do. So while its eyes can sense colors we can't, its brain doesn't seem to do anything with the color information.

Cirroc Lofton (Jake Sisko in Star Trek: Deep Space Nine) and sci-fi producer, Ryan T. Husk, critique, review and react to Star Trek: the Next Generation, episode 214, "The Icarus Factor."Producer: Ryan T. HuskAudio Engineer: Scott JensenExecutive Producers:Dr. Susan V. Gruner & Jason OkunAssociate Producers:Homer Frizzell Dr. Ann Marie Segal Eve England Yvette Blackmon-Tom TJ Jackson-BeyBill Victor Arucan Titus MohlerDarlena Marie Blander Dr. Mohamed Noor Tierney C. Dieckmann Anna Post Rex A. Wood Anil O. Polat Joe BalsarottiMike GuDr. Stephanie BakerDequeue Justine Norton-KertsonCarrie SchwentFaith HowellEdward Foltz AKA Crewman guyMai, Live From TokyoMatt BoardmanChris McGeeJustin WeirJake BarrettJane JorgensenHenry UngerJed ThompsonAllyson Leach-HeidJulie ManasfiMarsha "Classic" SchreierGreg K. WickstromSpecial Thanks to Malissa LongoEvery week, we rewatch an episode of The Next Generation, relive and review it. Join us!Rewatch TNG every week and get in on the discussion - we'd love to have you!If you enjoy our content please leave us a five star rating and comment/review.Support and join the community here:https://www.patreon.com/The7thRuleWatch the episodes with full video here:https://www.youtube.com/c/The7thRuleSocial media:https://twitter.com/7thRulehttps://www.facebook.com/The7thRule/https://www.facebook.com/groups/The7thRuleGet cool T7R merchandise here:https://the-7th-rule.creator-spring.com/Malissa Longo creates fun and functional Star Trek art at:https://theintrovertedrepublic.com/Get radical Trek swag at Ryan's online store here: https://star-trek-and-chill.myshopify.com/We continue The 7th Rule journey without our friend, our brother, Aron Eisenberg.He is still with us in spirit, in stories, in laughter, and in memories, and the show must go on.

Thanks to Anbo for suggesting Australopithecus! We'll also learn about Gigantopithecus and Bigfoot! Further reading: Ancient human relative, Australopithecus sediba, 'walked like a human, but climbed like an ape' Human shoulders and elbows first evolved as brakes for climbing apes You Won't Believe What Porcupines Eat Past tropical forest changes drove megafauna and hominin extinctions An Australopithecus skeleton [photo by Emőke Dénes - kindly granted by the author, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=78612761]: Show transcript: Welcome to Strange Animals Podcast. I'm your host, Kate Shaw. It's officially monster month, also known as October, so let's jump right in with a topic suggested by Anbo! Anbo wanted to learn about Australopithecus, and while we're at it we're going to talk about Gigantopithecus and Bigfoot. On our spookiness rating scale of one to five bats, where one bat means it's not a very spooky episode and five bats means it's really spooky, this one is going to fall at about two bats, and only because we talk a little bit about the Yeti and Bigfoot at the end. In 1924 in South Africa, the partial skull of a young primate was discovered. Primates include monkeys and apes along with humans, our very own family tree. This particular fossil was over a million years old and had features that suggested it was an early human ancestor, or otherwise very closely related to humans. The fossil was named Australopithecus, which means “southern ape.” Since 1924 we've discovered more remains, enough that currently, seven species of Australopithecus are recognized. The oldest dates to a bit over 4 million years old and was discovered in eastern Africa. Australopithecus was probably pretty short compared to most modern humans, although they were probably about the size of modern chimpanzees. A big male might have stood about 4 ½ feet tall, or 1.5 meters. They were bipedal, meaning they would have stood and walked upright all the time. That's the biggest hint that they were closely related to humans. Other great apes can walk upright if they want, but only humans and our closest ancestors are fully bipedal. In 2008 a palaeoanthropologist named Lee Rogers Berger took his nine-year-old son Matthew to Malapa Cave in South Africa. Dr. Berger was leading an excavation of the cave and Matthew wanted to see it. While he was there, Matthew noticed something that even his father had overlooked. It turned out to be a collarbone belonging to an Australopithecus boy who lived almost 2 million years ago. Later, Dr Berger's team uncovered more of the skeleton and determined that the remains belonged to a new species of Australopithecus, which they named Australopithecus sediba. More remains of this species were discovered later, including a beautifully preserved lower back. That discovery was important because it allowed scientists to determine that this species of Australopithecus had already evolved the inward curve in the lower back that humans still have, which helps us walk on two legs more easily. That was a surprise, since A. sediba also still shows features that indicate they could still climb trees like a great ape. It's possible that Australopithecus, along with other species of early humans, climbed trees at night to stay safe from predators. In the morning, they climbed down to spend the day mostly on the ground. One study published only a few weeks ago as this episode goes live suggests that the flexible shoulders and elbows that humans share with our great ape cousins originally evolved to help apes climb down from trees safely. Monkeys don't share our flexible shoulder and elbow joints because they're much lighter weight than a human or ape, and don't need as much flexibility to keep from falling while climbing down. Apes and hominins like humans can raise our arms straight up over our heads, and we can straighten our arms out completely flat.

Thanks to Tobey and Anbo for their suggestions this week! We're going to learn about some giant invertebrates! Further reading: The Invasive Giant African Land Snail Has Been Spotted in Florida A very big shell: The giant African snail is pretty darn giant [photo from article linked above]: The largest giant spider crab ever measured, and a person: Show transcript: Welcome to Strange Animals Podcast. I'm your host, Kate Shaw. This week we're going to learn about some giant invertebrates, suggested by Tobey and Anbo. Maybe they're not as big as dinosaurs or whales, but they're surprisingly big compared to most invertebrates. Let's start with Tobey's suggestion, about a big gastropod. Gastropods include slugs and snails, and while Tobey suggested the African trumpet snail specifically, I couldn't figure out which species of snail it is. But it did lead me to learning a lot about some really big snails. The very biggest snail known to be alive today is called the Australian trumpet snail, Syrinx aruanus. This isn't the kind of snail you'd find in your garden, though. It's a sea snail that lives in shallow water off the coast of northern Australia, around Papua New Guinea, and other nearby areas. It has a coiled shell that's referred to as spindle-shaped, because the coils form a point like the spindle of a tower. It's a pretty common shape for sea snails and you've undoubtedly seen this kind of seashell before if you've spent any time on the beach. But unless you live in the places where the Australian trumpet lives, you probably haven't seen a seashell this size. The Australian trumpet's shell can grow up to three feet long, or 91 cm. Not only is this a huge shell, the snail itself is really heavy. It can weigh as much as 31 lbs, or 14 kg, which is as heavy as a good-sized dog. The snail eats worms, but not just any old worms. If you remember episode 289, you might remember that Australia is home to the giant beach worm, a polychaete worm that burrows in the sand between high and low tide marks. It can grow as much as 8 feet long, or 2.4 meters, and probably longer. Well, that's the type of worm the Australian trumpet likes to eat, along with other worms. The snail extends a proboscis into the worm's burrow to reach the worm, but although I've tried to find out how it actually captures the worm in order to eat it, this seems to be a mystery. Like other gastropods, the Australian trumpet eats by scraping pieces of food into its mouth using a radula. That's a tongue-like structure studded with tiny sharp teeth, and the Australian trumpet has a formidable radula. Some other sea snails, especially cone snails, are able to paralyze or outright kill prey by injecting it with venom via a proboscis, so it's possible the Australian trumpet does too. The Australian trumpet is related to cone snails, although not very closely. Obviously, we know very little about the Australian trumpet, even though it's not hard to find. The trouble is that its an edible snail to humans and humans also really like those big shells and will pay a lot for them. In some areas people have hunted the snail to extinction, but we don't even know how common it is overall to know if it's endangered or not. Tobey may have been referring to the giant African snail, which is probably the largest living land snail known. There are several snails that share the name “giant African snail,” and they're all big, but the biggest is Lissachatina fulica. It can grow more than 8 inches long, or 20 cm, and its conical shell is usually brown and white with pretty banding in some of the whorls. It looks more like the shell of a sea snail than a land snail, but the shell is incredibly tough. The giant African snail is an invasive species in many areas. Not only will it eat plants down to nothing, it will also eat stucco and concrete for the minerals they contain. It even eats sand, cardboard, certain rocks, bones,

This week we have our annual updates and corrections episode, and at the end of the episode we'll learn about a really weird clam I didn't even think was real at first. Thanks to Simon and Anbo for sending in some corrections! Further reading: Lessons on transparency from the glass frog Hidden, never-before-seen penguin colony spotted from space Rare wild asses spotted near China-Mongolia border Aye-Ayes Use Their Elongated Fingers to Pick Their Nose Homo sapiens likely arose from multiple closely related populations Scientists Find Earliest Evidence of Hominins Cooking with Fire 153,000-Year-Old Homo sapiens Footprint Discovered in South Africa Newly-Discovered Tyrannosaur Species Fills Gap in Lineage Leading to Tyrannosaurus rex Earth's First Vertebrate Superpredator Was Shorter and Stouter than Previously Thought 252-Million-Year-Old Insect-Damaged Leaves Reveal First Fossil Evidence of Foliar Nyctinasty The other paleo diet: Rare discovery of dinosaur remains preserved with its last meal The Mongolian wild ass: The giant barb fish [photo from this site]: Enigmonia aenigmatica, AKA the mangrove jingle shell, on a leaf: Show transcript: Welcome to Strange Animals Podcast. I'm your host, Kate Shaw. This week is our annual updates and corrections episode, but we'll also learn about the mangrove jingle shell, a clam that lives in TREES. A quick reminder that this isn't a comprehensive updates episode, because that would take 100 years to prepare and would be hours and hours long, and I don't have that kind of time. It's just whatever caught my eye during the last year that I thought was interesting. First, we have a few corrections. Anbo emailed me recently with a correction from episode 158. No one else caught this, as far as I can remember. In that episode I said that geckos don't have eyelids, and for the most part that's true. But there's one family of geckos that does have eyelids, Eublepharidae. This includes the leopard gecko, and that lines up with Anbo's report of having a pet leopard gecko who definitely blinked its eyes. This family of geckos are sometimes even called eyelid geckos. Also, Anbo, I apologize for mispronouncing your name in last week's episode about shrimp. After episode 307, about the coquí and glass frogs, Simon pointed out that Hawaii doesn't actually have any native frogs or amphibians at all. It doesn't even have any native reptiles unless you count sea snakes and sea turtles. The coqui frog is an invasive species introduced by humans, and because it has no natural predators in Hawaii it has disrupted the native ecosystem in many places, eating all the available insects. Three of the Hawaiian islands remain free of the frogs, and conservationists are working to keep it that way while also figuring out ways to get them off of the other islands. Simon also sent me the chapter of the book he's working on that talks about island frogs, and I hope the book is published soon because it is so much fun to read! Speaking of frogs, one week after episode 307, an article about yet another way the glass frog is able to hide from predators was published in Science. When a glass frog is active, its blood is normal, but when it settles down to sleep, the red blood cells in its blood collect in its liver. The liver is covered with teensy guanine crystals that scatter light, which hides the red color from view. That makes the frog look even more green and leaf-like! We've talked about penguins in several episodes, and emperor penguins specifically in episode 78. The emperor penguin lives in Antarctica and is threatened by climate change as the earth's climate warms and more and more ice melts. We actually don't know all that much about the emperor penguin because it lives in a part of the world that's difficult for humans to explore. In December 2022, a geologist named Peter Fretwell was studying satellite photos of Antarctica to measure the lo...

Thanks to Eva and Anbo for suggesting the harpy eagle! Further reading: Crested Eagle Feeding a Post-Fledged Young Harpy Eagle Harpy eagle with a food [By http://www.birdphotos.com - Own work, CC BY 3.0, https://commons.wikimedia.org/w/index.php?curid=3785263]: The harpy eagle has great big feet and talons: The harpy eagle with its feather crown raised [photo by Eric Kilby]: The New Guinea harpy eagle looks similar to its South American cousin [By gailhampshire from Cradley, Malvern, U.K - New Guinea Harpy Eagle. Harpyopsis novaeguineae, CC BY 2.0, https://commons.wikimedia.org/w/index.php?curid=86187611]: Ruppell's griffon vulture: Show transcript: Welcome to Strange Animals Podcast. I'm your host, Kate Shaw. We've been talking about a lot of mammals lately, so let's have an episode about birds. Anbo suggested the harpy eagle not too long ago, and a much longer time ago Eva suggested the harpy eagle and other raptors. The word raptor can be confusing because it refers to a type of small theropod dinosaur as well as a type of bird. When referring to a bird, the term raptor includes eagles, hawks, vultures, owls, and other birds of prey. And that includes the harpy eagle. The harpy eagle lives throughout much of Central and South America, although not as far south as Patagonia. It has a wingspan up to about seven feet across, or over 2 meters, and like other raptors, females are larger than males. This isn't an especially big wingspan for an eagle, but that's because the harpy eagle hunts in forests and needs short, broad wings that allow it to maneuver through branches. The harpy eagle is a beautiful bird. It has a light gray head and darker gray or black body, and is white underneath with delicate black stripes on its leg feathers, with broader stripes on its tail and wings. It has a black ring around its neck, huge yellow feet with enormous talons, and a black bill. Each talon, which is the term for a raptor's claws, can be over 5 inches long, or 13 cm, while its feet in general are bigger than a grown man's hand, even if the man has especially big hands. Most striking of all is the harpy eagle's crest, also sometimes referred to as a crown. The crown is made of long, rounded feathers and most of the time they don't show very much. When a harpy eagle is alarmed, it raises the feather crown and poofs out the feathers on its face, which makes its head look bigger and sort of owl-shaped. The harpy eagle mostly lives in lowland rainforests. It mates for life and doesn't have babies every year. Every two or three years a harpy eagle pair will build a huge nest out of sticks in the top of the tallest tree they can find. The female lays two eggs, which the parents care for together. The female spends most of her time incubating the eggs while the male brings her food, although he will also take a turn incubating while she goes out to stretch her wings and do a bit of hunting herself. When the first egg hatches, the parents bring the baby lots of food and give it lots of attention--but they ignore the other egg at that point, which usually doesn't hatch as a result. A harpy eagle chick is all white at first, and although it can fly at around 6 months old, its parents will keep feeding it for almost another year. The harpy eagle is increasingly threatened due to habitat loss and poaching. Because it's such a big bird, many people shoot it because they think it's dangerous to livestock or children. But it mostly eats monkeys, sloths, kinkajous and coatis, iguanas, and other medium-sized animals. It's rare that it attacks livestock since it mostly hunts within the tree canopy for arboreal animals. If your lambs and chickens are sitting on tree branches, you already have a bigger problem than harpy eagles eating them. A captive breeding program has been started in various zoos around the world, while conservationists work to protect the harpy eagle's natural habit...

2023 情人节特备节目 ② 有别于常见的石蜡（Paraffin）、豆蜡（Soy Wax）；蜂蜡（Beeswax）成为了 ANBO Candle 的卖点之一。在情人节翌日，我们请来为生活增添情调的蜂蜡香薰蜡品牌，来听听他们究竟何故，在冠病疫情失业后会相中香薰蜡产业。在生活步调紧凑的时代，消费者要如何用最个人的香气，享受最亲近的一抹恬静呢？

One thing that the pandemic taught us was about the importance of self-love and self-pampering. When Anne and Boh lost their jobs during the pandemic, they decided to tap into the self-care industry and created the artisan handmade beeswax candle brand, Anbo. They unpack how different beeswax candles are compared to conventional ones, and their bee-sy journey. Image Credit: ANBO Facebook Page

One thing that the pandemic taught us was about the importance of self-love and self-pampering. When Anne and Boh lost their jobs during the pandemic, they decided to tap into the self-care industry and created the artisan handmade beeswax candle brand, Anbo. They unpack how different beeswax candles are compared to conventional ones, and their bee-sy journey. Image Credit: ANBO Facebook Page

While awaiting the upcoming Season 3, Your Generals go back to the final frontier to watch Season 2 of Star Trek: Lower Decks. Support Zac's Patreon: www.patreon.com/ThumbsJ Zac's Recommendation: Death of Doctor Strange (Comic) Tyler's Recommendation: Red Dwarf (TV) Check out all earVVyrm podcasts at www.earvvyrm.com Email us at generalnerderypod@gmail.com

Opnieuw een parlementaire enquête, terwijl de coronacrisis – eigenlijk – nog volop aan de gang is. Vandaag trapt de Tijdelijke commissie Corona af en oud-Kamervoorzitter Khadija Arib is gekozen tot voorzitter. De commissie moet de parlementaire enquête naar de coronacrisis voorbereiden. Liesbeth Staats bespreekt de taken van de commissie met Tweede Kamerlid Liane den Haan, die als voormalig directeur-bestuurder van ouderenbond ANBO de situatie in de verpleeghuizen van dichtbij zag, en met parlementair verslaggever Leendert Beekman.  See omnystudio.com/listener for privacy information.

Vandaag in Ochtendnieuws: Boze reacties op de afschaffing van het briefstemmen bij de gemeenteraadsverkiezingen, president Poetin en zijn Amerikaanse ambtgenoot Biden hebben gevideobeld over de hoog opgelopen spanningen rond Oekraïne en Bernard Hammelburg wijst op de Amerikaanse afhankelijkheid van China. De Russische president Poetin en zijn Amerikaanse ambtgenoot Biden hebben ruim twee uur gevideobeld over de hoog opgelopen spanningen rond Oekraïne. De Amerikanen vrezen dat Moskou een invasie plant, wat de Russen met klem ontkennen. Vooraf aan het gesprek zeiden woordvoerders dat de presidenten zullen hameren op de 'rode lijnen'. 'Het gesprek had geen enkele verrassing', zegt Rusland-correspondent Joost Bosman. Het is onacceptabel en onbegrijpelijk dat mensen bij de komende gemeenteraadsverkiezingen niet per brief kunnen stemmen. Veel ouderen hadden daar namelijk graag gebruik van willen maken, aangezien het coronavirus nog steeds veel slachtoffers maakt. Dat zegt ouderenbond ANBO tegen BNR. Column | China is nijdig op Joe Biden vanwege zijn ‘politieke boycot' tegen de Olympische Winterspelen. Dus geen officiële Amerikaanse delegatie, waarover de Chinese ambassade in Washington trouwens ook iets grappigs zegt: En is ‘nog helemaal niemand uitgenodigd,' en ‘het interesseert trouwens niemand of die mensen komen of niet.' Abonneren In Ochtendnieuws hoor je in 20 minuten het belangrijkste nieuws van de dag. Abonneer je op de podcast via bnr.nl/ochtendnieuws, de BNR-app, Spotify en Apple Podcasts. See omnystudio.com/listener for privacy information.

Vandaag in Ochtendnieuws: Boze reacties op de afschaffing van het briefstemmen bij de gemeenteraadsverkiezingen, president Poetin en zijn Amerikaanse ambtgenoot Biden hebben gevideobeld over de hoog opgelopen spanningen rond Oekraïne en Bernard Hammelburg wijst op de Amerikaanse afhankelijkheid van China. De Russische president Poetin en zijn Amerikaanse ambtgenoot Biden hebben ruim twee uur gevideobeld over de hoog opgelopen spanningen rond Oekraïne. De Amerikanen vrezen dat Moskou een invasie plant, wat de Russen met klem ontkennen. Vooraf aan het gesprek zeiden woordvoerders dat de presidenten zullen hameren op de 'rode lijnen'. 'Het gesprek had geen enkele verrassing', zegt Rusland-correspondent Joost Bosman. Het is onacceptabel en onbegrijpelijk dat mensen bij de komende gemeenteraadsverkiezingen niet per brief kunnen stemmen. Veel ouderen hadden daar namelijk graag gebruik van willen maken, aangezien het coronavirus nog steeds veel slachtoffers maakt. Dat zegt ouderenbond ANBO tegen BNR. Column | China is nijdig op Joe Biden vanwege zijn ‘politieke boycot' tegen de Olympische Winterspelen. Dus geen officiële Amerikaanse delegatie, waarover de Chinese ambassade in Washington trouwens ook iets grappigs zegt: En is ‘nog helemaal niemand uitgenodigd,' en ‘het interesseert trouwens niemand of die mensen komen of niet.' Abonneren In Ochtendnieuws hoor je in 20 minuten het belangrijkste nieuws van de dag. Abonneer je op de podcast via bnr.nl/ochtendnieuws, de BNR-app, Spotify en Apple Podcasts. See omnystudio.com/listener for privacy information.

Join the EARTH STATION TREKKERS as they step into the Anbo-jyutsu ring to tackle the FORTIETH EPISODE of every Star Trek series! Earth Station Trek is a part of the ESO Podcast Network, Executive Producer Mike Faber.

Join the EARTH STATION TREKKERS as they step into the Anbo-jyutsu ring to tackle the FORTIETH EPISODE of every Star Trek series! Earth Station Trek is a part of the ESO Podcast Network, Executive Producer Mike Faber. The post Earth Station Trek Episode Thirty-Nine – Fortieth Episodes appeared first on The ESO Network.

Everybody Loves Kyle Riker! Except for his son, well, at least until they swing big sticks at each other. After learning a little bit about Riker's childhood in the previous episode, we meet his father who comes along with great news: Star Fleet is offering Riker command of the USS Aries. The problem is that's in the middle of nowhere and Riker doesn't want to talk to his dad about the assignment. Kyle does talk to Dr. Pulaski, who would have married him in a hot minute. Meanwhile, Worf is acting all weird and Wesley is on the case to figure out that he just wants to be hit with painstiks in front of his family. All's well in this episode hosted by Kate and she ships Riker/Deanna hardcore while Jimmie is obsessed with Pulaski's many marriages, Erik loves the fight in the Anbo-jiutsu court, and Greg thinks Kyle Riker is a piece of shit.   We'd love to receive more feedback or questions we can read aloud and answer on episodes in the future so feel free to email letsReengage@gmail.com or message us on Twitter @ReEngageTNG! Host: Kate Jaeger (@jaegerlicious on Twitter and IG)  Panel: Erik Gratton (@erikfallsdown on Twitter & IG), Greg Tito (@gregtito on Twitter, @greg_tito on IG), and Jimmie G (@thejimmieg on IG & Twitter) Audio Editor: Greg Tito (@gregtito on Twitter, @greg_tito on IG) Logo artwork: @mojojojo_97 on Twitter, mojo97.com Theme music: Ryan Marth   Next up is "Pen Pals" s2e15 hosted by Jimmie!

2x03 Siempre nos quedará Tom Paris Precreditos: Boimler vuelve y shax resucita Nos acordamos de que hay noticias del mundillo trekkie Boimler quiere conocer a Tom Paris Shax y las resurrecciones en star trek Tendi y Mariner se van de misión Como mola Tendi de oriona 2x04 Mugato, Gumato Boimler y Rutherford practicando Anbo-jutsu A Boimler y Rutherford les gustan los juegos de mesa ¿Mariner es una agente secreta? Patingi el experto en Mugatos El timador y la capitana Tendi vs doctora T´Ana Síguenos en Twitter @OseraRadio en nuestra Web www.canalosera.com En nuestros grupo de Telegram o Discord buscanos como Canal Osera

There's a rumor going around that somebody works for Section 31. Boimler and Rutherford go 2 on 1 with Mariner, and the result is not pretty. Tendi goes on a secret scanning mission, Shaxs has a taste for the hunt, The Ferengi open up a sexy Mugato preservation, and someone likes to watch. -Brought to you by Section 31- 00:00 Episode 87 00:30 Looking at pulsars 00:51 Talking to the wall 01:25 Don't touch those! 02:20 Everybody heard 02:30 No Kids! 02:50 HR is listening 03:30 Thanks to Patreons! patreon.com/starfleetunderground 03:45 Grab vs Graze 04:45 Getting away with it on Facebook 05:10 Never been banned 05:26 Bitch, Please! 05:45 Banned! 06:00 Mark is not invited 07:20 New Patreon Member! Hi Ed! 08:20 Auction! Star Trek Pinball and Spock's Ears https://www.dailystartreknews.com/read/nimoy-family-adds-star-trek-pinball-machine-and-spock-ears-to-auction-benefiting-copd-research 09:00 Surprise! 09:55 Annie Wersching joins Season 2 of Picard at the Borg Queen! https://deadline.com/2021/09/star-trek-picard-annie-wersching-recurring-for-season-2-1234826556/ 11:55 Tim Russ helps NASA! https://nerdist.com/article/star-trek-voyager-tim-russ-nasa-spot-asteroid/ 14:24 Extra Testicular Life 15:20 7" Bat'leth and 8" Vulcan Lirpa https://blog.trekcore.com/2021/08/factory-entertainment-debuts-scaled-down-star-trek-prop-replicas/ 17:30 Star Trek: Lower Decks S2R4 - "Mugato, Gumato" 17:45 Teaser: "Fight like a girl!" 18:00 Expecting an ass kicking, but... 18:20 Just run! 18:50 Shaxs 10 min early 19:25 Not Mariner's HoloGym 19:48 Holodeck was on Easy Mode 20:15 2 on 1 Anbo-jyutsu 21:00 Future from the '80s 21:21 Act I - "Physicals, Poisoned Horns, Black Ops, Oh My!" 22:40 She's Black Ops 23:00 That's just a kinky thing 23:40 The Knife Thing 24:45 Finger Dipping and Eating 25:40 Denobulans get Puffy 26:13 Believing Rumors 26:45 Where did Honus come from? 27:40 Their Genitals are Sensitive to Phaser Fire 28:30 Mugato, Gumato origins 30:00 Whip it! 30:40 Act II - "Don't Lose Your Head to a Black Ops Killer Using the Lowest Tractor Factor" 32:20 Mugato Porn, The Stroking of the Horn 33:00 Trapped in a log 33:46 Free Joke! 35:35 The Tractor Factor 36:40 Use you special powers! 37:00 Tricorder to the face! 37:30 She's totally Section 31! 38:15 Tendi's Scanning Mission 38:45 Stevens needs milk 39:26 Act III - "Physicals are for Pussies" 41:20 Rumors help with Dating? The Mugato Twins 41:50 Caitian Chasing 42:50 You want me to see the doctor? I AM the Doctor! 43:30 Tendi's Arm 43:50 Bazooka Powerpoint 44:20 Last Outpost Style Ferengi 46:15 Moogie's Goodies 47:10 Scamming Starfleet? 47:50 Pooper Scooper 48:13 Tangy 48:25 Shaxs and T'Ana Fan-Fic? 49:00 Inappropriate Hairball 49:44 Next week! "Embarrassment of Dooplers" 50:20 Star Trek Day September 8th - https://www.startrek.com/day 51:30 A Tribble? No, that's a windscreen 52:15 The Ratings 54:40 He Did It Multiple Times 55:20 Shout out to Patreons! 56:00 Back into a wall - Glory Hole?! 56:42 In Memory of Steffan Fredsti 58:00 Be Safe! - Thanks for listening! 58:50 Where's the wall? Now on Patreon! patreon.com/starfleetunderground Email: thecollective@starfleetunderground.com Website: starfleetunderground.com Twitter: twitter.com/StarfleetUnderG Instagram: instagram.com/starfleetunderground Facebook: facebook.com/starfleetunderground YouTube: www.youtube.com/Qtsy16 Explicit

Lietuvoje mokiniams pamažu grįžtant į mokyklas, kai kuriose šalyse jos nebuvo uždarytos. Specialistai Belgijoje džiaugiasi, kad valdžia į ugdymo procesą pažiūrėjo atsakingai – mokyklos čia veikė iš esmės visus metus, o kitą savaitę atlaisvinami paskutiniai ribojimai. Kaip belgai sugebėjo laikyti mokyklas atidarytas ir netapti dideliu COVID‘o židiniu – aiškinasi LRT žurnalistas Briuselyje Mindaugas Laukagalis.Lietuvoje minint Spaudos atgavimo, kalbos ir knygos dieną, o savaitės pradžioje - ir Pasaulinę spaudos laisvės dieną, didelį nerimą tarptautinei bendruomenei ir toliau kelia blogėjanti padėtis kaimyninėje Lenkijoje. Šalies vyriausybės atstovai šį savaitgalį turėtų aptarti laikinai pristabdytus planus apmoestinti nepriklausomus leidinius reklamos mokesčiu - šis ketinimas vasario pradžioje Lenkijoje sukėlė plataus masto protestus. Valdžiai kėsinantis į žiniasklaidos laisvę, Briuselis raginamas imtis griežtesnių veiksmų. Dalies ekspertų teigimu, be planuojamų direktyvų, teigiamų pokyčių gali atnešti ir sprendimai dėl Bendrijos biudžeto. Išsamiau šia tema rubrikoje “Naujienų žemėlapis” domisi Karolina Panto.Kas žinotina pasiskiepijus viena, dviem vakcinom, įgijus tam tikrą imunitetą? Gydytoja, klinikinė farmakologė Simona Stankevičiūtė ir LSMU profesorius Alvydas Laiškonis.Gegužės 7-oji – Spaudos atgavimo, kalbos ir knygos diena.LRT, siekdama skatinti visuomenę domėtis viešosios kalbos vartosenos reiškiniais ir juos fiksuoti, kasmet skelbia LRT žodžio ir LRT posakio rinkimus. Šiandien bus skelbiami nugalėtojai – komisijos išrinktas LRT žodis bei posakis ir visuomenės išrinktas LRT žodis bei posakis. Mūsų pašnekovė – LRT Kalbos kultūros redaktorė, šių rinkimų sumanytoja Lina Smolskienė ir Valstybinės Lietuvių kalbos komisijos pirmininkas Audrys Antanaitis.Savaitės įvykių apžvalga. LRT apžvalgininkė, žurnalistė Liepa Želnienė ir Vilniaus universiteto rektoriaus patarėjas, apžvalgininkas Paulius Gritėnas.Vytauto Didžiojo karo muziejuje neeilinis įvykis – iš palubių nuleistas inžinieriaus, lakūno ir pedagogo Antano Gustaičio tarpukariu sukurtas lėktuvas ANBO-1. Vienvietis žemasparnis monoplanas ANBO-I – vienintelis išlikęs per visus karus ir okupacijas.Jūratė Anilionytė.Savaitės komentaras. Autorė – apžvalgininkė Rita Miliūtė.Ved. Gabija Narušytė

Pek Lum, co-founder, and CEO of Auransa believes that a lot fewer drugs would fail in Phase 2 clinical trials if they were tested on patients predisposed to respond. The problem is finding the sub-populations of likely high-responders in advance and matching them up with promising drug compounds. That’s Auransa's specialty.The Palo Alto, CA-based drug discovery startup, formerly known as Capella Biosciences, has a pipeline of novel compounds for treating cancer and other conditions identified through machine learning analysis of genomic data and other kinds of data. It’s closest to the clinical trial stage with a DNA-binding drug for liver cancer (AU-409) and is also working on drugs for prostate cancer and for protecting the heart against chemotherapy drugs. The company says it discovered AU-409 as part of a broad evaluation of data sets on a range of close to 30 diseases. The company’s discovery process uses a platform called the SMarTR Engine that uses hypothesis-free machine learning to identify druggable targets and compounds as well as likely high-responder patients. Lum  calls it “interrogating gene expression profiles to identify patient sub-populations.” The company believes this approach can identify unexpected connections between diverse molecular pathways to disease, and that it will lead to progress in drug development for intractable conditions with poorly understood biology, including cancer and autoimmune, metabolic, infectious, and neurological diseases.Lum co-founded Auransa with Viwat Visuthikraisee in 2014 and is the chief architect behind its technology. Before Auransa, she was VP of Product, VP of Solutions, and Chief Data Scientist at Ayasdi (now SymphonyAyasdiAI), a Stanford spinout known for building hypothesis-free machine learning models to detect patterns in business data. Before that, she spent 10 years as a scientific director at Rosetta Inpharmatics, a microarray and genomics company that was acquired by Merck. She has bachelor's and master's of science degrees in biochemistry from Hokkaido University in Japan and a Ph.D. in molecular biology from the University of Washington, where she studied yeast genetics.Please rate and review MoneyBall Medicine on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:• Launch the “Podcasts” app on your device. If you can’t find this app, swipe all the way to the left on your home screen until you’re on the Search page. Tap the search field at the top and type in “Podcasts.” Apple’s Podcasts app should show up in the search results.• Tap the Podcasts app icon, and after it opens, tap the Search field at the top, or the little magnifying glass icon in the lower right corner.• Type MoneyBall Medicine into the search field and press the Search button.• In the search results, click on the MoneyBall Medicine logo.• On the next page, scroll down until you see the Ratings & Reviews section. Below that, you’ll see five purple stars.• Tap the stars to rate the show.• Scroll down a little farther. You’ll see a purple link saying “Write a Review.”• On the next screen, you’ll see the stars again. You can tap them to leave a rating if you haven’t already.• In the Title field, type a summary for your review.• In the Review field, type your review.• When you’re finished, click Send.• That’s it, you’re done. Thanks!TRANSCRIPTHarry Glorikian: I’m Harry Glorikian, and this is MoneyBall Medicine, the interview podcast where we meet researchers, entrepreneurs, and physicians who are using the power of data to improve patient health and make healthcare delivery more efficient. You can think of each episode as a new chapter in the never-ending audio version of my 2017 book, MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market. If you like the show, please do us a favor and leave a rating and review at Apple Podcasts.For every drug candidate that makes it all the way through the three phases of clinical trials to win FDA approval, there are about 20 others that fail along the way. Phase 2, where drug makers have to prove that a new drug is safer or more effective than existing treatments, is where a lot of drugs falter.But often, it’s not because the drugs don’t work. Sometimes it’s just because they weren’t tested on the right patients. Meaning, the people in the treatment group didn’t happen have the right genes or gene expression profiles to respond. If you could find enough patients who were likely high-responders and try your new drug just on them, your chances of approval might go way up. The tough part is identifying those subpopulations in advance and matching them up with promising drug compounds.That’s where a company like Auransa comes in. It’s a Palo Alto startup that has built an AI platform called the SMarTR Engine. The engine uses public datasets on gene expression to identify subtypes of molecular diseases and predict what kinds of compounds might work against specific subtypes. Auransa used the engine to discover a drug for liver cancer that’s about to enter clinical trials. And it’s licensing out other drugs it discovered for prostate cancer and for protecting the heart against the effects of cancer chemotherapy.Some of the ideas baked into the SMarTR Engine come from a sub-field of artificial intelligence called hypothesis-free machine learning. And joining us this week to explain exactly what that means is our guest Pek Lum. She’s a biochemist and molecular biologist who worked at the microarray maker Rosetta Inpharmatics and the software company Ayasdi before founding Auransa in 2014. And she says one of the real revolutions in drug development is that almost every disease can be divided up into molecular subtypes that can best be treated using targeted drugs.Harry Glorikian: Pek, welcome to the show.Pek Lum: Thank you. Pleasure to be here.Harry Glorikian: You know, I always try to ask this opening question when I start the show to give the listeners a good idea of of what your company does. But you guys are in in drug discovery. What tell us how people understand what is the basic approach that you guys have. And I'll get into the special sauce later. But what do you guys do in the drug discovery space?Pek Lum: No, that's a really great question in the sense that when we first started in about five years ago, we... I've always been in the drug discovery field in the sense that I worked for over 20 years ago at that time in a company called Rosetta Inpharmatics, which is really pushing the cutting edge of thinking about using molecular data. Right. And to solve the mysteries of biology. And I was extremely lucky to be one of the core members in when we were very small. And then that really kind of put me in the sense put me in the stage where I could think about more than just one gene. Right. Because the technology was just kind of getting really kind of I would say not rolling forward, like propelling forward, with microarrays.Harry Glorikian: Yes.Pek Lum: So I was part of the whole movement and it was really amazing to be kind of like, you know, in the show as it runs, so to speak. And so and then Merck bought us after we went public and worked for Merck and Co. for another eight years, really learning how technology, how we should apply technology, how we can apply technology, molecular data, RNA data, DNA data to a drug discovery pipeline. And really kind of figured out that there are many things that the pharmaceutical world does very well, but there are many things that it also fails in and that how can we do it better? So I've always been in the mindset of, when starting Auransa with my co-founder, How do we do it better? And not only just do it better, but do it very differently so that we can address the most, I would say critical problems. So Auransa is really a company started by us to address the problem of why drugs actually fail a lot when we go into a Phase II efficacy trial. Right. Is not like the drug is bad or toxic. And most of the time is you can find enough responders to make your clinical trial a success.Pek Lum: And that cause, I guess, drugs actually made to maybe against one target. You don't really think about the biology that much at the beginning or the biology responders. So Auransa was really created to think about first, the heterogeneity of the disease and the heterogeneity of patient response. So we start from looking at molecular data of the disease from the get go. We take RNA, is really the RNA world is coming back with the vaccines.Harry Glorikian: Right.Pek Lum: And the RNA has always been fascinating because it tells you about the activity of the cell, of a normal cell versus a disease cell. So we use RNA transcriptomes right, transcriptomics to study the biology and the heterogeneity. So our algorithms, there are many algorithms, one of the first algorithms of the engine is really to look at the biology of heterogeneity, whether we can subdivide a disease into more homogeneous categories before doing anything.Harry Glorikian: Right. Yeah, I remember when, because when I was at Applied Biosystems, I remember Applied Biosystems, Affymetrix and then Stephen Friend starting this and like, you know, it was all starting back then. And I want to say we sort of had an idea of what we were doing, but compared to now, it's like, wow, how naive we were back then compared to how much this whole space has evolved. And it's interesting you mention, you know, RNA and its activity because in a couple of weeks, I'm actually going to be talking to a spatial genomics company so that you get a better idea from a visual standpoint of which cells are actually activating and which aren't.Harry Glorikian: But so, you've got an interesting professional career, and I say that because you were working at a big data analytics company for a while that was utilizing an approach that was hypothesis-free machine learning, where the machine was sort of identifying unique or aspects that you should be paying attention to. Maybe that it was seeing that instead of you going in there saying, let's just look over here, you could see what the machine was seeing for you. How much can you tell us a little bit about that experience? And then how did that influence what you're doing now? Because I have to believe that they superimpose at some level.Pek Lum: Right. I think, you know, ever since my first job at Rosetta and then my subsequent jobs really kind of culminated into this into this tech, as you see today. Right. All this experience and certainly experience while being a founding member of a small team at that time of Ayasdi, which is the software company, has been also an eye-opening experience for me because we were trying to create, using a very old mathematical idea called topology, or TDA, really start to figure out whether there's maybe there's some things that can't be learned. Right. And so typical machine learning methods need a training set or a test. But there are just some things where you don't really know what the ground truth is. So how do you do that? So that's the idea of like I say, the hypothesis-free approach. And the approach that that that the tech company, the software company that we built is really around the idea that not everything can be learned. But you can actually adapt some very interesting ideas around a hypothesis-free approach and then use it in a machine learning AI framework. So I definitely have been influenced by that thinking, you know, as I as we built the software.Harry Glorikian: Right.Pek Lum: And also, when we were Rosetta, we were generating in parallel, data on thousands of genes. And often at that time we were called, "Oh, you're just going fishing," you know, but fishing is not a bad idea because you don't really know which part of the ocean you need to go to catch your Blue Marlin, for example, right?Harry Glorikian: Yeah, no, no, absolutely.Pek Lum: Fish a little bit, not the whole ocean, but, you know, to get some, I would say, boundaries. Right. So in that sense, to me, a hypothesis-free approach gives you the boundaries where you can look. So, you know, so the experience, definitely the idea that you can use methods or thinking, algorithms, that could help you in a field where you do not know the ground truth. Like patient heterogeneity, I would say nobody really can pinpoint and say, OK, I can say that, oh, this is THE subtype, these are THE markers. And therefore, I'm going to go after this. And there are many. I guess, for example, you can think of a Herceptin as a great example, right, but when you first started, you know, it was like, wow, OK, you're going to go after a target. And then the idea of really kind of subtyping breast cancer, you know, I don't know, 20, 30 years ago. Right. And we're still learning about, you know, in a patient heterogeneity and we're just beginning to scratch the surface. So for Auransa, we wanted to use a method very much like the thinking that and the idea that we had, you know, when we were when I was at Ayasdi, is that you could search with some parameters, you know, a very complex space without needing to say, this is my hypothesis. This is that one gene, because we all know that if you have a target, you know ... to have to respond you need the target. But if you have the target, it doesn't mean you're going to respond. Because things below the target or above the target are much more complex than that.Harry Glorikian: Correct. And I always feel that there's, you know, I always call them low hanging fruit. Like the first one is, OK, well, it's either luck or skill, but I got to one level. But then you start to see people that are not responding. So that means something else is going on and there's subtypes. Right. So it's funny how we always also call it "rare diseases" in these smaller population. I'm pretty convinced that at some point everything is going to be a rare disease. Right. Because of the subtypes that we're going to start to see. I mean, even we're seeing in a neurological now, or Alzheimer's. There's subtypes of Alzheimer’s. No! Really? Shocking. Amazing to me that there's subtypes. Right. We've been dealing with this for ages. And I do believe that these technologies are so good at highlighting something where a human might not have seen it, might not have understood it. You know, I was I was interviewing actually I just posted it today on imaging and agriculture. And they were saying that sometimes the machine sees things that we don't fully understand how it sees it, but it sees it and points it out, which allows us now to dig into it and be able to sort of identify what that unique feature is that the machine has pulled out. I'm not sure I want drug discovery and drugs being based on something we don't fully understand, but the machine highlighting something for us that then we can go dig into, I think is an interesting greenfield space that that we need to explore more.Pek Lum: Right. I think you're absolutely right. You know, when we first started Auransa, that was the idea that we had. And then my co-founder and I thought, what if we find like hundreds of subtypes? We're never going to be able to make a drug again a hundred subtypes. So let's hope we find a small enough number of buckets that we can say this is approximately what it looks like, to be able to be practical to find drugs against those subtypes. So when we talk about subtypes, we are talking about you're absolutely right, it's like a leaf on a tree and that we have to cut it off at one point. Enough that things that, OK, this is homogeneous enough that actually makes sense out of it. And that's where the engine, that's what the engine does. Basically, it takes data, very, very complex data, things that we could never figure that out ourselves and say this approximately five, six buckets. So we've actually not found hundreds of subtypes, otherwise we probably would not have started Auransan, because it would have been impossible. But instead, we find n of one, but maybe a five to seven subtypes at most. That is enough for us to say, the machine says, OK, it is homogeneous enough, go for this. So that's kind of where we are, where we start at Auransa. And I think that's an important concept because people often thought about precision medicine as being, oh, I'm going to make a medicine for you and you only. But actually you could learn from, say, breast cancer, and that's approximately people with estrogen-receptor-positive tumors. And then you will likely respond to a drug like Tamoxifen. And even though we know that the response rate is only about, I think maybe 30, 40 percent. Right. But that's really good. At least at this poibt. So that's where we how we think about the engine as a shining light on a homogeneous enough population that we can actually make a drug against that.Harry Glorikian: Yeah. So that sort of leads us into you have this technology that you've termed SMarTR, S-M-A-R-T-R engine. Right. What does that stand for?Pek Lum: You know, that's my one of my rare occasion where I put my marketing hat on. I don't like marketing all. And we so and you notice the Mar is big-M, little-a-r. So S is for Subpopulation. Markers. Targets. And Redefining. Because I needed it to be Smartr.Harry Glorikian: Ok, ok. So and when you like when you've described this in the papers that I've looked at it, it's a machine learning mathematical statistical approaches, highly automated and totally runs in the cloud. So can you give us a little more color on the sort of the highly automated, and why is that so important?Pek Lum: Right. It's important because it comes from my own experience of working with, like, amazingly talented implementations and data scientist at the at Merck or I know how it goes where biologists will often ask them for something and they would run their magic and they'd give us an Excel sheet or a PowerPoint. Right. It's always a one-off one of those and one of that because you know, biologists are kind of one-off. So the idea of of us building this engine is not just equipping it with algorithms. So first of all, we don't have one algorithm, a hammer looking for a nail. We have a problem to solve. The problem is how to find novel drugs, drugs that people have never thought about, for patient populations that will respond.Pek Lum: So with that in mind, we built a pipeline of algorithms that starting from thinking about heterogeneity, to understanding preclinical models that reflect the biology of human subtypes, to predicting drugs and targets for those, and getting biomarkers for the patients when we go to the clinic. And we have different algorithms for each step of the pathway. So instead of having my team do a one-off thing, we know that if we don't do good software engineering it's going to be problematic because first it's going to take a really long time. This will be kind of higgledy piggledy in Excel sheets and we might be able to solve one thing. But to do this as a platform and as a pipeline builder, it would be impossible without good engineering practices. So we wanted to put this in, like I say, in a framework where everything is connected, so where it gets to run faster and faster through better algorithms, through better software engineering. And this really kind of came from my experience to at Ayasdi, a software engineering, a software firm. And also my co-founder who is a physicist and a software engineer, that we need to have good software practices. So what we did was we built first. We don't want any servers. Everything is done on AWS and is done in modules. So we create algorithms for each part of the pipeline, of the in silico pipeline. And then we have in such a way that when we take data in, when we ingest data, that we also automate it, and then by the time it ingest data and it spits out, I would say, what subtypes of disease, what biomarkers could be used in the clinic, what targets are interesting to you, what compounds from our digital library of compounds may be effective for that. Everything is more or less connected and could be done up in the cloud and now it finishes in about 24 hours.Harry Glorikian: When do humans look at it to say hmmm, makes sense. Or maybe we need to tweak the model a little. Right. Because it's not making sense. When does that happen?Pek Lum: So we, it happens at several steps. So within our engine we actually have benchmarks in there that we run periodically. You know, for example we have about about eight to ten data sets that we have for breast cancer, thousands of patient tumors. And we know approximately that it should be discovering, and it has discovered ER+ flavored subtypes, ERBB2, HER2+ subtypes, triple negative subtypes. So that is kind of like the rails that we put into our engine as well to make sure that when we actually do tweak an algorithm, it still has its wheels. But what we do is at this point, we generate out all the in-between data, but it's kept on the cloud. And once it's up, when it outputs the the list of things, the biologists actually, I would say the biologists with a knack for computation, we look at it and I myself look at it. I love to do data analysis in my spare time when I'm not doing CEO stuff. And we can see that we will look at once it's done that it also allows you...Ok, so this is an interesting one. The engine on the cloud outputs all of this. And right now, let's say my CSO, who is not a computational person, or me, or whoever really would be kind of a big pain to kind of go up and install the stuff and look at the things, some things you can't see. So what we did as a company is to build another kind of software, which is the visualization software on top of that.Pek Lum: So we have on our other end a visualization software that we call Polo because it's exploring that basically connects everything the SMarTR engine has done into something that's visualizable. It has a URL, we go to it and let's say, for example, my CSO wants to know, OK, the last one you did on head and neck cancer, you know, how many subtypes did you find? What is the biology, what's the pathway? And it could do all of that by him just going then looking at things. Or he can actually type in his favorite gene and then see what the favorite gene actually is predicted for how it behaves across over 30 diseases, and you can do that all at his fingertips, so we have that part of the engine as well, which is not the engine. We call it Polo, which is our visualization platform.Harry Glorikian: Right. It's funny because one of the first times I interviewed Berg Pharma and they were talking about their system, I was like, if you put on a pair of VR glasses, could you see the interconnectivity and be able to look in a spatial.... I was on another planet at the time, but it was a lot of fun sort of thinking about how you could visualize how these things interact to make it easy. Because human beings I mean, you see a picture. Somehow we're able to process a picture a lot faster than all this individual data. I think it... I just slow down. I rather look at a visual if it's possible.Pek Lum: It is so important because, you know, even though the engine is extremely powerful now, takes it 24 hours to finish from data input to kind of spitting out this information that we need. Visualization and also like the interpretation and just kind of making sure kind of like the human intelligence. Can I keep an eye on things. The visualization platform is so, so important. That's why I feel like that we did the right thing in making and taking time, putting a bit of resources to make this visualization platform for our preclinical team who actually then needs to look at it and go, OK, these are the drugs that are that are predicted by the engine. Can we actually have an analog of it or does it have development legs? Does it make sense? Does the biology makes sense. And so now we're basically connected everything. So you can click on a, you can find a drug in a database and it will pop up, you know, the structure and then it will tell you, hey, this one has a furan ring. So maybe you might want to be careful about that. This one has a reactive oxygen moiety. You might want to be careful about that. As we grew the visualization platform, we got feedback from the users. So we put more and more things in there, such that now it has a little visualization module that you can go to. And if you ever want to know something, I can just, I don't have to email my data scientist at 1:00 am in the morning saying, hey, can you send me that Excel sheet that has that that particular thing on it that I want to know from two weeks ago? I can just go to Auransa's Polo, right? As long as I have wi-fi. Right. And be able to be self-sufficient and look at things and then ask them questions if things look weird or, you know, talk to my CEO and say, hey, look at this. This is actually pretty interesting. And this one gets accessed by anybody in Auransa as long as you have Wi-Fi.Harry Glorikian: So so it's software development and drug development at the same time. Right. It's interesting because I always think to myself, if we ever, like, went back and thought about how to redo pharma, you'd probably tear apart the existing big pharma. Other than maybe the marketing group, right, marketing and sales group, you tear apart the rest of it and build it completely differently from the ground up? It was funny, I was talking to someone yesterday at a financial firm, a good friend of mine, and it's her new job and she's like, my job is to fully automate the back to the back end and the middle and go from 200 people down to 30 people because we're fully automating it. I'm like, well, that sounds really cool. I'm not really thrilled about losing the other 170 people. But with today's technology, you can make some of these processes much more automated and efficient. So where do you get your data sets that you feed your programs?Pek Lum: Yeah, let me tell you this. We are asked this a lot of times. And just kind of coming back again for my background as an RNA person. Right. One thing that I think NIH and CBI did really well over 20 years ago is to say, guys, now we no longer doing a one gene thing. We have microarrays and we're going to have sequencing. There's going to be a ton of data. We need to start a national database. Right. And it will enable, for anybody that publishes, to put the data into a coherent place. And even with big projects like TCGA, they need things that could be accessed. Right. So I think it is really cool that we have this kind of, I would say, repository. That unfortunately is not used by a lot of people because, you know, everything goes in. That's a ton of heterogeneity. So when we first started the company, before we even started the company, we thought about, OK, where is it that we can get data? We could spend billions of dollars generating data on cells, pristine data, but then it would never represent what's in the clinical trials without what's out there in the human the human world, which is the wild, wild west. Right. Heterogeneity is abundant. So we thought, aha, a repository like, you know, like GEO, the Gene Expression Omnibus, right, and ANBO or TCGA allows this kind of heterogeneity to come in and allows us the opportunity to actually use the algorithms which actually have algorithms that we look for. We actually use to look for heterogeneity and put them into homogeneity. These kind of data sets. So we love the public data sets. So because it's free, is generated by a ton of money. It is just sitting there and it's got heterogeneity like nobody's business. Like you could find a cohort of patients that came from India, a cohort of patients that came from North Carolina, and group of patients that came from Singapore and from different places in the US and different platforms. So because the algorithms at first that studied heterogeneity is actually, I would say, platform independent, platform agnostic, we don't use things that are done 20 years ago. They were done yesterday. And what we do is we look at each one of them individually and then we look for recurrent biological signals. So that's the idea behind looking for true signals, because people always say, you go fishing, you may be getting junk out. Right?Pek Lum: So let's say, for example, we go to, the engine points to a spot in the sea, in the ocean, and five people go, then you're always fishing out the same thing, the Blue Marlin, then you know that there is something there. So what we do is we take each data set, runs it through an engine and say these are the subtypes that I find. It does the same thing again in another data set and say these are the things that I find. And then it looks for recurrence signals, which is if you are a artifact that came from this one lab over here, or some kind of something that is unique to this other code over there, you can never find it to be recurrent. And that's a very weird, systematic bias, you know, so so because of that, we are able to then very quickly, I would say, get the wheat and throw away the chaff. Right. And basically by just looking by the engine, looking at looking for recurring signals. So public data sets is like a a treasure trove for Auransa because we can use it.Harry Glorikian: So you guys use your engine to I think you identified something unexpected, a correlation between plant-derived flavonoid compound and the heart. I think it was, you found that it helps mitigate toxic effects in a chemotherapy drug, you know. Can you say more about how the system figured that out, because that sounds not necessarily like a brand-new opportunity, but identifying something that works in a different way than what we thought originally.Pek Lum: Right, exactly. So in our digital library, let me explain a little bit about that. We have collected probably close to half a million gene expression profiles. So it's all RNA gene expression based, representing about 22,000 unique compounds. And these are things that we might generate ourselves or they are in the public domain. So any compound that has seen a live cell is fair game to our algorithms. So basically you put a compound, could be Merck's compound, could be a tool compound, could be a natural compound, could be a compound from somewhere. And it's put on a cell and gene expression was captured. And those are the profiles or the signatures that we gather. And then the idea is that, because remember, we have this part of the engine where we say we're going to take the biology and study it and then we're going to match it or we're going to look for compounds or targets. When you knock it down, who's gene expression actually goes the opposite way of the the disease. Now, this is a concept that is not new, right. In the sense that over 20 years ago, I think Rosetta probably was one of the first companies that say, look, if you have a compound that affects the living cell and it affects biology in a way that is the opposite of your disease, it's a good thing. Right thing. So that's the concept. But, you know, the idea then is to do this in such a way that you don't have to test thousands of compounds.Harry Glorikian: Right.Pek Lum: That is accurate enough for you to test a handful. And that's what we do. And by putting the heterogeneity concept together with this is something extremely novel and extremely important for the engine. And so with this kind of toxicity is actually an interesting story. We have a bunch of friends who are spun off a company from Stanford and they were building cardiomyocytes from IPS cells to print stem cells. And they wanted to do work with us, saying that why do we work together on a cool project? We were just starting out together and we thought about this project where it is a highly unmet medical need, even though chemotherapy works extremely well. Anthracyclines, it actually takes heart, takes a toll. There is toxicity and is it's a known fact. And there's only one drug in the market and a very old drug in the market today. And there is not much attention paid to this very critical aspect. So we thought we can marry the engine. At that time were starting up with oncology. We still we still are in oncology, and they were in cardiomyocytes. So we decided to tackle this extremely difficult biology where we say, what is a how does chemotherapy affect heart cells and what does the toxicity look like? So the engine took all kinds of data sets, heart failure data sets, its key stroke and cells that's been treated with anthracyclines. So a ton of data and look for homogeneity and signals of the of the toxicity.Pek Lum: So this is a little bit different from the disease biology, but it is studying toxicity. And we then ask the engine to find compounds that we have in our digital library, that says that what is the, I would say the biology of these compounds when they hit a living cell that goes the opposite way of the toxicity. And that's how we found, actually we gave the company probably about seven, I forget, maybe seven to 10 compounds to test. The one thing that's really great about our engine is that you don't have to test thousands of compounds and it's not a screen because you screened it in silico. And then it would choose a small number of compounds, usually not usually fewer than 30. And then we able to test and get at least a handful of those that are worth looking into and have what they call development legs. So this I would say this IPSC cardiomyocyte system is actually quite complex. You can imagine that to screen a drug that protects against, say, doxorubicin is going to be a pretty complicated screen that can probably very, very hard to do in a high throughput screen because you have to hit it with docs and then you have to hit it with the compounds you want to test and see whether it protects against a readout that is quite complex, like the beating heart.Pek Lum: And so we give them about, I think, seven to 10 and actually four of them came out to be positive. Pretty amazing. Out of the four, one of them, the engine, noticed that it belonged to a family of other compounds that looked like it. So so that was really another hint for the the developers to say, oh, the developers I mean, drug developers to say, this is interesting. So we tested then a whole bunch of compounds that look like it. And then one of them became the lead compound that we actually licensed to a a pharma company in China to develop it for the Chinese market first. We still have the worldwide rights to that. So that's how we tackled toxicity. And I think you might have read about another project with Genentech, actually, Roche. We have a poster together. And that is also the same idea, that if you can do that for cardio tox, perhaps you can do it for other kinds of toxicity. And one of them is actually GI tox, which is a very common toxicity. Some of them are rate limiting, you might have to pull a drug from clinical trials because there's too much GI tox or it could be rate limiting to that. So we are tackling the idea that you can use to use machine, our engine, to create drugs for an adjuvant for a disease, a life-saving drug that otherwise could not be used properly, for example. So that's kind of one way that we have to use the engine just starting from this little project that we did with the spin out, basically.Pek Lum: So basically, you're sort of, the engine is going in two directions. One is to identify new things, but one is to, I dare say, repurpose something for something that wasn't expected or wasn't known.Pek Lum: That is right. Because it doesn't really know. It doesn't read papers and know is it's a repurposed drug or something. You just put in it basically, you know, the gene expression profiles or patterns of all kinds of drugs. And then from there, as a company, we decided on two things. We want to be practical, right. And then we want to find novel things, things that, and it doesn't matter where that comes from, as long as the drug could be used to do something novel or something that nobody has ever thought of or it could help save lives, we go for it. However, you know, we could find something. We were lucky to find something like this flavanol that has never been in humans before. So it still qualifies as an NCE, actually, and because it's just a natural compound. So so in that sense, I would say maybe is not repurposing, but it's repositioning. I don't know from it being a natural compound to being something maybe useful for heart protection. Pek Lum: Now for our liver cancer compound, it is a total, totally brand-new compound. The initial compound that the engine found is actually a very, very old drug. But it was just a completely different thing and definitely not suitable for cancer patients the way it is delivered.Harry Glorikian: This is the AU 409?Pek Lum: Correct? Entirely new entity. New composition of matter. But the engine gave us the first lead, the first hit, and told us that we analyzed over a thousand liver tumors and probably over a thousand normal controls, found actually three subtypes, two of them the main subtypes and very interesting biology. And the engine predicted this compound that it thinks will work on both big subtypes. We thought this is interesting. But we look at the compound. You know, it's been in humans. It's been used. It's an old drug. But it could never be given to a cancer patient. And so and so our team, our preclinical development team basically took that and say, can we actually make this into a cancer drug? So we evaluated that and thought, yes, we can. So we can basically, we analogged it. It becomes a new chemical. Now it's water-soluble. We want to be given as a pill once a day for liver cancer patients. So so that's how we kind of, as each of the drug programs move forward, we make a decision, the humans make a decision, after the leadds us to that and say can we make it into a drug that can be given to patients?Harry Glorikian: So where does that program stand now? I mean, where is it in its process or its in its lifecycle?Pek Lum: Yeah, it's actually we are GMP manufacturing right now. It's already gone through a pre-IND meeting, so it's very exciting for us and it's got a superior toxicity profile. We think it's very well tolerated, let's put it that way. It could be very well tolerated. And it's it's at the the stage where we are in the GMP manufacturing phase, thinking about how to make that product and so on.Harry Glorikian: So that that begs the question of do you see the company as a standalone pharma company? Do you see it as a drug discovery partner that that works with somebody else? I'm you know, it's interesting because I've talked to other groups and they start out one place and then they they migrate someplace else. Right. Because they want the bigger opportunities. And so I'm wondering where you guys are.Pek Lum: Yeah, we've always wanted to be, I say we describe ourselves as a technology company, deep tech company with the killer app. And the killer app is drug discovery and development especially. And we've always thought about our company as a platform company, and we were never shy about partnering with others from the get go. So with our O18 our team, which is a cardioprotection drug, we out-licensed that really early, and it's found a home and now is being developed. And then we moved on to our liver cancer product, which we brought a little bit further. Now it's in GMP manufacturing. And we're actually looking for partners for that. And we have a prostate cancer compound in lead optimization that will probably pan out as well. So we see ourselves as being partners. Either we co-develop, or we out-license it and maybe one day, hopefully not too far in the future, we might bring one or two of our favorite ones into later stage clinical trials. But we are not shy about partnering at different stages. So we are going to be opportunistic because we really have a lot to offer. And also one thing that we've been talking to other partners, entrepreneurs, is that using our engine to form actually other companies, to really make sure the engine gets used and properly leveraged for other things that Auransa may not do because we just can't do everything.Harry Glorikian: No, that's impossible. And the conversation I have with entrepreneurs all the time, yes, I know you can do it all, but can we just pick one thing and get it across the finish line? And it also dramatically changes valuation, being able to get what I have people that tell me, you know, one of these days I have to see one of these A.I. systems get something out. And I always tell them, like, if you wait that long, you'll be too late.Harry Glorikian: So here's an interesting question, though. And jumping back to almost the beginning. The company was named Capella. And you change the name to Auransa.Pek Lum: That's right.Harry Glorikian: And so what's the story behind that? Gosh, you know.Harry Glorikian: When somebody woke up one morning and said, I don't like that name.Pek Lum: It's actually pretty funny. So we so we like to go to the Palo Alto foothills and watch the stars with the kids. And then one day we saw Capella. From afar, you look at it, it's actually one star. You look at closer, it's two stars. Then closer, it's four stars. It's pretty remarkable. And I thought, OK, we should name it Capella Biosciences. Thinking we are the only ones on the planet that are named. So we got Capella Biosciences and then probably, we never actually had a website yet. So we were just kind of chugging along early days and then we realized that there was a Capella Bioscience across the pond in the U.K. We said what? How can somebody be named Capella Bioscience without an S? So I actually called up the company and said, “Hey, we are like your twin across the pond. We're doing something a little different, actually completely different. But you are Capella Bioscience and I am Capella Biosciences. What should we do?” And they're like, “Well, we like the name.” We're like, “Well, we like it too.” So we kind of waited for a while. And but in the meantime, I started to think about a new name in case we need to change it. And then we realized that one day we were trying to buy a table, one of those cool tables that you can use as a ping pong table that also doubles as a as a conference room table. So we called up this New York City company and they said, oh, yeah, when are you going to launch the rockets into space. We're like what? So apparently, there's a Capella Space.Harry Glorikian: Yeah, OK.Pek Lum: Well, that's the last straw, because we get people tweeting about using our Twitter handle for something else. And so it's just a mess. So we've been thinking about this other name, and I thought this is a good name. Au means gold. And ansa is actually Latin for opportunity, which we found out. So we're like oh, golden opportunity. Golden answer. That kind of fits into the platform idea. Auransa sounds feminine. I like it. I'm female CEO. And I can get auransa.com. Nobody has Auransa. So that is how Auransa came to be.Harry Glorikian: Well, you got to love the…I love the Latin dictionary when I'm going through there and when I'm looking for names for a company, I've done that a number of times, so. Well, I can only wish you incredible success in your journey and what you're doing, it's such a fascinating area. I mean, I always have this dream that one day everybody is going to share all this data and we're going to move even faster. But I'm not holding my breath on that one when it comes to private companies. But it was great to talk to you. And I hope that we can continue the conversation in the future and watch the watch the progression of the company.Pek Lum: Thank you, Harry. This has been really fun.Harry Glorikian: That’s it for this week’s show. We’ve made more than 50 episodes of MoneyBall Medicine, and you can find all of them at glorikian.com under the tab “Podcast.” You can follow me on Twitter at hglorikian. If you like the show, please do us a favor and leave a rating and review at Apple Podcasts. Thanks, and we’ll be back soon with our next interview.  

Welcome aboard the Great Derelict! This week Andy is joined by Oliver to look at Sports in the future (or a long time ago, in a galaxy far far away) from Post apocalyptic gladiatorial games, to the mystic arts of Anbo-jyutsu! The Wacky Races Fury Road can be found here - https://imgur.com/gallery/3OIXq You can find Oliver on Twitter https://twitter.com/oliver_monk and http://percytrollcast.blogspot.co.uk/ And you can find more of Andy and his other casts over at Rogue Two Media - http://www.roguetwomedia.com/ - https://twitter.com/GreatDerelict - https://www.facebook.com/groups/GreatDerelict/

Lot woont in Nederland, haar vriend Matt in Amerika. De twee hebben elkaar sinds maart niet gezien, omdat er vanwege de coronacrisis nog steeds geen vluchten gaan tussen Europa en de Verenigde Staten. Dit weekend sloten ze elkaar tóch in de armen, op Aruba. Het eiland in de Caraïbische Zee biedt een uitkomst voor ‘gemengde koppels', vertelt Lot Franken in de corona-update. Verder in de podcast: verslaggever Gijsbert Termaat onderzocht of ouderen nog wel op vakantie durven tijdens de coronacrisis. Veel senioren geven aan thuis te blijven, terwijl het volgens ouderenorganisatie ANBO juist zo belangrijk is dat deze groep eropuit trekt na al die maanden in isolement.

De coronamaatregelen worden soepeler, maar dat is niet voor iedereen goed nieuws. De zogenoemde 'kwetsbare groepen' lopen meer risico op besmetting en moeten zelf maatregelen nemen om beschermd te blijven. Vaak betekent dat meer isolatie dan de afgelopen weken al het geval was. Honderdduizenden mensen die normaal prima functioneren in de samenleving staan aan de kant en voelen zich vergeten. Mensen met een chronische ziekte of een verlaagde weerstand bijvoorbeeld en ook al die zeventigplussers die gewoon thuis wonen en zich fit en vitaal voelen. In De Dag pleiten ouderenbond Anbo en Iederin, het netwerk voor mensen met een beperking of chronische ziekte, voor een oplossing voor deze groepen. Ze kunnen niet zomaar apart gezet worden, zegt Iederin. De Anbo denkt aan meer testmogelijkheden voor ouderen. Verder vertelt Jennifer Brouwer hoe het is om in deze tijd met MS te leven.

Een week geleden vroegen we op NU.nl om ervaringen met werkdruk in de zorg te delen. Daarop werd veel gereageerd. Mensen voelen de druk en dat is ook niet zo gek, want de vraag om zorg is anders dan voorheen.In deze podcast laten we meerdere NUjij'ers aan het woord die werkzaam zijn in de ouderenzorg en we praten met Atie Schipaanboord, coordinator Public Affairs bij de ANBO, de belangenorganisatie voor senioren.

How do we even begin to cover the pure awesomeness that is Anbo-jyutsu? When Riker is offered his own command of a starship, Riker's estranged father, Kyle, pops up on the Enterprise to give him the briefing. Though it seems that Kyle arrives with good intentions, Riker still has some issues to work out over why his father abandoned him so long ago. Meanwhile, Wesley tries to figure out what is eating Worf - and hoodwinks Data and Geordi to help him out. The Worf screams return as Engineer Jim and Ensign Harry hit the Anbo-jyutsu mat to cover "The Icarus Factor" - Season 2, Episode 14 of Star Trek: The Next Generation! Enjoy! "Ensign" Harry - @HSJIII Hailing Frequencies - @HailFrequencies WRITE-IN - HailFrequencies@gmail.com

Games, Sports, and Hobbies on TNG.   What does the crew of The Next Generation do to relax and spend their free time? What do the activities that they pursue when they're not on duty say about the main characters on the show?   In this episode of Earl Grey, hosts Amy Nelson, Richard Marquez, and Justin Oser discuss a selection of games, sports, and hobbies that we see on The Next Generation. Activities covered include poker, fencing, acting, dancing, horseback riding, phaser target practice, Strategema, Dom-jot, Anbo-jyutsu, and Mok'bara. Chapters Intro (00:01:14)  Feedback from Babel Conference (00:02:34)  Poker (00:05:46)    Fencing (00:13:50)    Worf’s Calisthenics (00:18:35)  Acting (00:24:02)  Horseback Riding (00:29:50)  Phaser Target Practice (00:35:06)  Anbo-jyutsu (00:40:52)  Strategema (00:44:36)  Dom-jot (00:46:31)  Honorable Mentions (00:49:50)  Final Thoughts (00:56:23)  Runtime: 1 hour 6 minutes 42 seconds   Hosts Richard Marquez, Justin Oser, Amy Nelson   Production Richard Marquez (Editor and Producer) Justin Oser (Producer) Amy Nelson (Producer) Tony Robinson (Producer) C Bryan Jones (Executive Producer) Matthew Rushing (Executive Producer) Ken Tripp (Executive Producer) Norman C. Lao (Associate Producer) Michael E Hueter (Associate Producer) Thomas Appel (Associate Producer) Justin Oser (Associate Producer) Richard Marquez (Production Manager) Tony Robinson (Show Art) Brandon-Shea Mutala (Patreon Manager)

Assisted dying has no more committed opponent than the Catholic Church. They have thrown resources, and the full weight of their political influence, against it wherever it has been proposed. That’s why the words of Sydney’s Archbishop Anthony Fisher – one of Australia’s most senior Catholic clerics, and a man who commands the ear of many politicians – are worth listening to. Archbishop Anthony Fisher, debating ethicist Peter Singer at Sydney Town Hall, 13 August 2015 — Source: YouTube Listen closely, and what you’ll hear is a masterclass in FUD: Fear, Uncertainty, and Doubt. The same seeds sown by opponents of assisted dying to great effect down the years. What lies inside those little seeds of FUD? In this episode – for the first time – we’re going to find out. 'I think it's almost unheard of that the elderly feel more as a burden and the opposite is true. They feel empowered by this, it strengthens them.' Joeri Veen, spokesperson for ANBO – a peak body representing the Dutch elderly – discussing the impact of euthanasia laws on ANBO’s members Please note: this podcast is not about suicide. If you are interested in increasing your understanding of suicide and how to support someone experiencing suicidal ideation, visit the Conversations Matter or beyondblue websites.If you (or someone you know) require immediate assistance, contact one of the following 24/7 crisis support services: Lifeline (13 11 14), Suicide Call Back Service (1300 659 467), MensLine (1300 78 99 78), beyondblue (1300 22 4636), Kids Helpline (1800 55 1800) or eheadspace (1800 650 890). Hear more Embed player Listen Better Off Dead: interview with Tom Keneally Tom Keneally is one of Australia’s best-loved and most successful authors – and a former Catholic seminarian. Here, he discusses the belief of some Catholics that pain can purify, and that suffering redeems the soul. Know more Video: 'Q&A: Facing Death' – Australian Broadcasting Corporation, 9 November 2015 Article: 'FactCheck Q&A: Were 550 babies killed last year under Dutch euthanasia laws?', by Colleen Cartwright (reviewed by Lorana Bartels and Jan F. Koper) – The Conversation, 16 November 2015 Opinion: 'Assisted dying: Sorting the facts from the half-truths and the misleading statements', by Ross Fitzgerald – Age, 15 December 2015 Video: 'Lord Carey on Assisted Dying – July 2014' – Christina Summers, 19 August 2015 Website: Christians Supporting Choice for Voluntary Euthanasia Video: 'Euthanasia debate: Professor Peter Singer versus Archbishop Anthony Fisher OP' – Sydney University Catholic Society, 13 August 2015 In this episode Anthony Fisher Nancy Elliott Catherine Glenn Foster Nick Cooling Alex Schadenberg John Fleming Henk Reitsema Kevin Yuill Joan Hume Illya Soffer Pierre Gyselinck Bob Joondeph Joeri Veen Mie Moerenhout Cheryll Brounstein Eduard Verhagen Our theme music was composed by Zig Zag Lane for Zapruder's Other Films, and edited by Jon Tjhia. Music used in this episode includes 'Untitled #8 (Popplagith)' (Sigur Rós), 'Hold Me Through' (Luke Howard), 'I Might be Wrong' (Radiohead) and 'Forty-Eight Angels' (Paul Kelly). Your stories If you're suffering, or someone you love has died badly – in a hospital, in palliative care, in a nursing home, or at home – add your voice and tell your story here. Further information Better Off Dead is produced by Thought Fox and the Wheeler Centre. Executive producers Andrew Denton and Michael Williams. Producer and researcher Bronwen Reid. For Better Off Dead, the Wheeler Centre team includes Director Michael Williams, Head of Programming Emily Sexton, Head of Marketing and Communications Emily Harms, Projects Producer Amita Kirpalani and Digital Manager Jon Tjhia. Editing, sound design and mix on this episode is by Martin Peralta. Additional editing by Bec Fary and Jon Tjhia. Thank you Thanks to field producer Emily Sexton, and to Paul Kelly and Sony ATV for the use of his song ‘Forty Eight Angels’. The series Subscribe in iTunes, or your favourite podcast app. #betteroffdeadpod Better Off Dead is produced by Thought Fox in partnership with the Wheeler Centre. It is written and created by Andrew Denton for Thought Fox.